RhumbLine Advisers’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.44M | Sell |
376,187
-565
| -0.1% | -$8.1K | ﹤0.01% | 1365 |
|
|
2025
Q4 | $5.36M | Sell |
376,752
-45,126
| -11% | -$443K | ﹤0.01% | 1364 |
|
|
2025
Q3 | $3.32M | Sell |
421,878
-12,474
| -3% | -$88.8K | ﹤0.01% | 1633 |
|
|
2025
Q2 | $2.49M | Sell |
434,352
-5,999
| -1% | -$38.7K | ﹤0.01% | 1771 |
|
|
2025
Q1 | $3.59M | Buy |
440,351
+28,383
| +7% | +$263K | ﹤0.01% | 1520 |
|
|
2024
Q4 | $3.88M | Sell |
411,968
-138
| -0% | -$1.43K | ﹤0.01% | 1545 |
|
|
2024
Q3 | $4.4M | Sell |
412,106
-22,506
| -5% | -$245K | ﹤0.01% | 1495 |
|
|
2024
Q2 | $4.31M | Buy |
434,612
+19,491
| +5% | +$200K | ﹤0.01% | 1475 |
|
|
2024
Q1 | $4.89M | Buy |
415,121
+12,481
| +3% | +$160K | ﹤0.01% | 1433 |
|
|
2023
Q4 | $5.71M | Sell |
402,640
-13,480
| -3% | -$153K | 0.01% | 1335 |
|
|
2023
Q3 | $5.06M | Buy |
416,120
+1,372
| +0.3% | +$17.7K | 0.01% | 1335 |
|
|
2023
Q2 | $5.21M | Sell |
414,748
-12,588
| -3% | -$149K | 0.01% | 1352 |
|
|
2023
Q1 | $4.74M | Buy |
427,336
+33,941
| +9% | +$418K | 0.01% | 1351 |
|
|
2022
Q4 | $4.8M | Buy |
393,395
+20,970
| +6% | +$236K | 0.01% | 1300 |
|
|
2022
Q3 | $3.89M | Buy |
372,425
+33,645
| +10% | +$375K | 0.01% | 1377 |
|
|
2022
Q2 | $3.64M | Buy |
338,780
+52,874
| +18% | +$435K | 0.01% | 1438 |
|
|
2022
Q1 | $2.71M | Sell |
285,906
-26,692
| -9% | -$250K | ﹤0.01% | 1658 |
|
|
2021
Q4 | $3.61M | Sell |
312,598
-3,683
| -1% | -$41K | ﹤0.01% | 1555 |
|
|
2021
Q3 | $3.02M | Buy |
316,281
+7,018
| +2% | +$71.8K | ﹤0.01% | 1658 |
|
|
2021
Q2 | $2.98M | Buy |
309,263
+2,436
| +0.8% | +$23.8K | ﹤0.01% | 1733 |
|
|
2021
Q1 | $3.03M | Sell |
306,827
-31,780
| -9% | -$492K | ﹤0.01% | 1696 |
|
|
2020
Q4 | $7.82M | Buy |
338,607
+3,773
| +1% | +$77.2K | 0.01% | 1084 |
|
|
2020
Q3 | $4.73M | Sell |
334,834
-76,062
| -19% | -$1.11M | 0.01% | 1206 |
|
|
2020
Q2 | $6.2M | Buy |
410,896
+38,709
| +10% | +$472K | 0.01% | 1072 |
|
|
2020
Q1 | $3.44M | Buy |
372,187
+15,150
| +4% | +$144K | 0.01% | 1243 |
|
|
2019
Q4 | $3.48M | Buy |
357,037
+17,371
| +5% | +$159K | 0.01% | 1482 |
|
|
2019
Q3 | $2.72M | Buy |
339,666
+19,791
| +6% | +$215K | 0.01% | 1559 |
|
|
2019
Q2 | $3.99M | Buy |
319,875
+64,532
| +25% | +$819K | 0.01% | 1325 |
|
|
2019
Q1 | $3.47M | Buy |
255,343
+2,989
| +1% | +$36.5K | 0.01% | 1382 |
|
|
2018
Q4 | $2.42M | Buy |
252,354
+81,792
| +48% | +$899K | 0.01% | 1529 |
|
|
2018
Q3 | $2.06M | Sell |
170,562
-13,250
| -7% | -$185K | ﹤0.01% | 1642 |
|
|
2018
Q2 | $2.87M | Buy |
183,812
+10,306
| +6% | +$156K | 0.01% | 1473 |
|
|
2018
Q1 | $2.61M | Buy |
173,506
+15,275
| +10% | +$232K | 0.01% | 1459 |
|
|
2017
Q4 | $2.28M | Buy |
158,231
+1,350
| +0.9% | +$18.5K | ﹤0.01% | 1554 |
|
|
2017
Q3 | $2.37M | Buy |
156,881
+18,443
| +13% | +$244K | 0.01% | 1511 |
|
|
2017
Q2 | $1.39M | Buy |
138,438
+2,690
| +2% | +$21.6K | ﹤0.01% | 1774 |
|
|
2017
Q1 | $968K | Buy |
135,748
+4,958
| +4% | +$31.3K | ﹤0.01% | 1935 |
|
|
2016
Q4 | $650K | Buy |
130,790
+11,646
| +10% | +$80.6K | ﹤0.01% | 2093 |
|
|
2016
Q3 | $882K | Buy |
119,144
+11,856
| +11% | +$80.1K | ﹤0.01% | 1888 |
|
|
2016
Q2 | $586K | Buy |
107,288
+12,170
| +13% | +$85.1K | ﹤0.01% | 2098 |
|
|
2016
Q1 | $804K | Buy |
95,118
+1,170
| +1% | +$8.29K | ﹤0.01% | 1936 |
|
|
2015
Q4 | $911K | Sell |
93,948
-9,180
| -9% | -$82.7K | ﹤0.01% | 1870 |
|
|
2015
Q3 | $1.44M | Buy |
103,128
+21,613
| +27% | +$339K | ﹤0.01% | 1544 |
|
|
2015
Q2 | $1.15M | Buy |
+81,515
| New | +$980K | ﹤0.01% | 1780 |
|
|
2014
Q2 | – | Sell |
-27,686
| Closed | -$57K | – | 3027 |
|
|
2014
Q1 | $57K | Sell |
27,686
-1,020
| -4% | -$2.55K | ﹤0.01% | 2960 |
|
|
2013
Q4 | $67K | Hold |
28,706
| – | – | ﹤0.01% | 2988 |
|
|
2013
Q3 | $67K | Sell |
28,706
-267
| -0.9% | -$670 | ﹤0.01% | 2958 |
|
|
2013
Q2 | $68K | Buy |
+28,973
| New | +$89K | ﹤0.01% | 3285 |
|
Other funds holding FOLD
VCM
PCM
VPM
GCL
RhumbLine Advisers's FOLD Position: Q1 2026 in Review
RhumbLine Advisers reduced its Amicus Therapeutics (FOLD) stake by 0.15% in Q1 2026, selling an estimated $8.1K and leaving 376,187 shares worth $5.44M. The position accounts for ﹤0.01% of the portfolio, ranked #1365.
RhumbLine Advisers first reported a position in FOLD in Q2 2013 and has held it in 48 quarters since. The position peaked at $7.82M in Q4 2020. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.
- RhumbLine Advisers held 376,187 shares of Amicus Therapeutics worth $5.44M as of Q1 2026.
- RhumbLine Advisers sold 565 Amicus Therapeutics shares in Q1 2026, an estimated $8.1K.
- Amicus Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #1365 holding.
- RhumbLine Advisers first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 48 quarters since.
- RhumbLine Advisers's Amicus Therapeutics position peaked at $7.82M in Q4 2020.
- 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.
Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.